LifeMD Launches Novo Nordisk Wegovy Subscription Program, Offering First Branded GLP-1 Telehealth Access With Up To $1,200 Annual Patient Savings

LifeMD, Inc. (NASDAQ: LFMD) has launched a subscription program for Novo Nordisk's Wegovy (semaglutide), marking the first branded GLP-1 telehealth access. This program offers eligible patients up to $1,200 in annual savings for injectable formulations and $600 for oral therapy, enhancing patient access and treatment adherence. The collaboration with Novo Nordisk has evolved since 2025, now providing a comprehensive care experience that includes virtual visits and ongoing clinical oversight.